50 Participants Needed

Suzetrigine for Oral Contraceptive Interaction

MI
Overseen ByMedical Information
Age: 18 - 65
Sex: Female
Trial Phase: Phase 1
Sponsor: Vertex Pharmaceuticals Incorporated
Must be taking: Oral contraceptives
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you have conditions that affect how drugs are absorbed or processed in your body, you might not be eligible to participate.

How does the drug Suzetrigine differ from other treatments for oral contraceptive interaction?

Suzetrigine is unique because it is being studied specifically for its interaction with oral contraceptives, which is not commonly the focus of other treatments. This makes it potentially novel in understanding and managing how it affects the effectiveness of birth control pills.12345

What is the purpose of this trial?

The purpose of this study is to evaluate the effect of SUZ on the pharmacokinetics of oral contraceptives.

Eligibility Criteria

This trial is for healthy female participants who don't smoke or haven't smoked in the last year, have a body mass index (BMI) between 18.0 and 30.0, and weigh over 50 kilograms. It's designed to see how Suzetrigine affects the way their bodies process birth control pills.

Inclusion Criteria

My BMI is between 18.0 and 30.0.
I have not smoked for at least a year.
I weigh more than 50 kg.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Part A

Participants receive a single dose of DRSP/EE on Days 1 and 20, and SUZ every 12 hours from Days 7 through 25

4 weeks

Treatment Part B

Participants receive a single dose of NGM/EE on Days 1 and 22, and SUZ every 12 hours from Days 9 through 29

4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Suzetrigine
Trial Overview The study is testing Suzetrigine (SUZ), a medication intended for pain management, to understand its impact on oral contraceptives specifically DRSP/EE and NGM/EE which are common forms of birth control pills.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Part B: SUZ with Norgestimate/Ethinyl Estradiol (NGM/EE)Experimental Treatment2 Interventions
Participants will receive a single dose NGM/EE on Days 1 and 22. Participants will also receive SUZ every 12 hours (q12h) from Days 9 through 29.
Group II: Part A: SUZ with Drospirenone/Ethinyl Estradiol (DRSP/EE)Experimental Treatment2 Interventions
Participants will receive a single dose of DRSP/EE on Days 1 and 20. Participants will also receive SUZ every 12 hours (q12h) from Days 7 through 25.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vertex Pharmaceuticals Incorporated

Lead Sponsor

Trials
267
Recruited
36,100+
Dr. David Altshuler profile image

Dr. David Altshuler

Vertex Pharmaceuticals Incorporated

Chief Medical Officer since 2020

MD, PhD

Dr. Reshma Kewalramani profile image

Dr. Reshma Kewalramani

Vertex Pharmaceuticals Incorporated

Chief Executive Officer since 2020

MD, trained in internal medicine and nephrology

Findings from Research

Co-administration of lamotrigine with a combined oral contraceptive significantly reduced the plasma levels of lamotrigine, indicating a clinically relevant pharmacokinetic interaction that may require dosage adjustments for lamotrigine.
While the combined oral contraceptive's effectiveness was not compromised (as indicated by unchanged ethinyloestradiol levels and maintained suppression of ovulation), a modest decrease in levonorgestrel levels was observed, along with reports of intermenstrual bleeding in some subjects.
The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects.Sidhu, J., Job, S., Singh, S., et al.[2018]
In a study involving 35 HIV-infected women, those taking protease inhibitors (PI) showed significantly higher serum concentrations of norethindrone (NET), indicating that PIs inhibit the metabolism of this progestin-only contraceptive.
The findings suggest that progestin-only pills like NET may be more effective in HIV-infected women on PI regimens, as evidenced by a 1.5 times higher area under the curve for NET in the PI group compared to controls.
Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women.Atrio, J., Stanczyk, FZ., Neely, M., et al.[2021]
In two studies involving 27 and 29 healthy women, oral tazarotene (up to 6 mg) did not significantly alter the pharmacokinetics of the oral contraceptive Ortho-Novum 1/35, indicating that tazarotene can be safely coadministered without affecting contraceptive efficacy.
The hormonal levels of norethindrone, ethinylestradiol, LH, and FSH remained within acceptable ranges, suggesting that tazarotene does not interfere with the hormonal balance maintained by the contraceptive, ensuring its effectiveness.
Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.Yu, Z., Yu, D., Walker, PS., et al.[2018]

References

The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. [2018]
Effect of protease inhibitors on steady-state pharmacokinetics of oral norethindrone contraception in HIV-infected women. [2021]
Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. [2018]
Pharmacokinetic drug interactions with oral contraceptives. [2018]
Clinical pharmacokinetics of contraceptive steroids. An update. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security